NXGL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the user's beginner investment level, long-term strategy, and available funds, Nexgel Inc (NXGL) is not a strong buy at this time. The stock lacks clear positive technical signals, has weak financial performance, and no immediate catalysts to drive significant growth. A hold position is recommended until further clarity from the upcoming earnings report or other significant developments.
The stock exhibits bearish technical indicators. The MACD is below zero and negatively contracting, RSI is neutral at 32.038, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 0.671, with resistance at 0.879. The stock is trading near support levels, but no strong reversal signals are present.
Upcoming Q4 and FY 2025 earnings report and conference call on March 31, 2026, could provide more clarity.
Analysts have lowered the price target from $6 to $2 due to dilution concerns from financing the Celularity acquisition. No significant trading activity from hedge funds, insiders, or Congress. Technical indicators suggest bearish momentum.
In Q3 2025, revenue dropped by -0.20% YoY to $2,934,000, net income fell by -5.77% YoY to -$653,000, and EPS declined by -27.27% YoY to -0.08. However, gross margin improved by 7.84% YoY to 42.37%.
Maxim maintains a Buy rating but lowered the price target from $6 to $2, citing dilution concerns from financing the Celularity acquisition. Analysts believe the acquisition could be transformative but remain cautious.
